Navigation Links
Hollis-Eden Presents New Interim Data From Prostate Cancer Phase I/II Clinical Studies of Apoptone (HE3235) at AACR Molecular Targets and Cancer Therapeutics Conference
Date:11/16/2009

i> (HE3235) or any other investigational drug candidate; the Company's future capital needs; the Company's ability to obtain additional funding; the ability of the Company to protect its intellectual property rights and to not infringe the intellectual property rights of others; the development of competitive products by other companies; and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, Hollis-Eden undertakes no obligation to update or revise the information contained in this press release as a result of new information, future events or circumstances arising after the date of this press release.

SOURCE Hollis-Eden Pharmaceuticals, Inc.


'/>"/>
SOURCE Hollis-Eden Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Hollis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone(R) (HE3235) at Molecular Targets and Cancer Therapeutics Conference
2. Hollis-Eden Pharmaceuticals Receives NASDAQ Notification Related to Minimum Bid Price
3. Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
4. Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
5. Curemark Presents at Springboard Enterprises Life Sciences Forum
6. NexBio(R) Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
7. Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
8. DIATHERIX Laboratories Presents at Homeland Security Conference
9. Sanofi Pasteur Presents Safety Data on Menactra(R) Vaccine Given to Infants at Infectious Disease Society Meeting
10. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
11. Sinobiopharma Presents Highlights from Unaudited First Quarter Financial Results for the 3 Month Period Ended August 31, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... 4, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) announced ... Form 20-F for the fiscal year ended December 31, ... The annual report on Form 20-F contains information regarding ... the area of cancer immune checkpoints. This project aims ... specificity and binding in targeting certain identified immune checkpoints. ...
(Date:5/4/2015)... Boston, MA (PRWEB) May 04, 2015 ... solutions for drug discovery and life science research, ... 5.0 , the latest version of its enterprise ... for biopharma R&D enables more efficient discovery and ... holistic approach to integrate and address protein optimization ...
(Date:5/4/2015)...   Tocagen Inc. , a clinical-stage immuno-oncology ... ongoing investigational studies were presented at the 11 th ... of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) ... Washington, D.C. In addition, ... FDA and continues to advance towards initiation of ...
(Date:5/1/2015)... N.C. (PRWEB) May 01, 2015 ... Charlotte (UNC Charlotte) spin-out company, announced that Pinku Mukherjee, ... the UNC Board of Governors’ highest faculty honor. ... to humanity’s welfare , for her innovative research and ... Max Gardner Award represents a crowning moment in my ...
Breaking Biology Technology:Tikcro Technologies Files Annual Report on Form 20-F for the Year Ended December 31, 2014 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 2Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 3Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 4Tocagen Presents Updated Interim Survival Data from Ongoing Clinical Studies at American Association of Neurological Surgeons (AANS)/Congress of Neurological Surgeons (CNS) Section on Tumors 5OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award 2
... Imaging,Diagnostic Systems, Inc., (OTC Bulletin Board: IMDS), ... I returned to the company three months ago to,assume ... Board; we have,received many phone calls from our shareholders ... my first priority, I have,recently secured a tiered debenture ...
... Conn., Aug. 5 Marinus Pharmaceuticals, a,developer of ... disorders, has appointed John Krayacich as president,and chief ... leading,the company,s drug and business development for ganaxolone, ... and chelerythrine, a pre-clinical,schizophrenia candidate., Mr. Krayacich ...
... Group, P.A., Deliver Faster Recovery,Fewer Complications for ... Aug. 5 Thoracic Group, P.A., (http://www.thoracicgroup.com ... services,and a national leader of minimally-invasive video ... completion of its 5,000th VATS,surgical procedure. Highly ...
Cached Biology Technology:CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc. 2CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc. 3CEO's Letter to Shareholders of Imaging Diagnostic Systems, Inc. 4Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 2Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 3Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer 4Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure 2Renowned NJ-Based Video Assisted Thoracic Surgery (VATS) Team Completes 5,000th Successful Procedure 3
(Date:4/10/2015)... DUBLIN , April 10, 2015 ... the addition of the "Security Competitive Profiles - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , NEC will continue to ... solutions to the market, with a company focus on ... solution anticipated. Winning opportunities in the ...
(Date:4/8/2015)...  Infinisource, a leading provider of SaaS-based Human Capital ... leading supplier of biometric identification and security solutions, ... advanced biometrically-enabled time clock, the companies announced today. ... setting a bold, new standard for the collection ... and mid-size employer. When connected to the iSolved ...
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
Breaking Biology News(10 mins):NEC Security Competitive Profile 2015 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3
... Catching a football. Maneuvering through a room full of ... fore. Most would agree these seemingly simple actions require us ... of Cognitive Science at Rensselaer Polytechnic Institute Mark Changizi argues ... It takes our brain nearly one-tenth of a second to ...
... hold empirical knowledge that tuna aggregate under floating objects, ... or even large marine mammals. There is still no ... 20 years have seen purse-seine fishery operators take advantage ... floating rafts equipped with buoys which act as FADs. ...
... in green tea may be able to stave off ... (OSA), according to a new study published in the ... American Journal of Respiratory and Critical Care Medicine. ... through drinking water, on rats who were intermittently deprived ...
Cached Biology News:Crystal (eye) ball: Study says visual system equipped with 'future seeing powers' 2Crystal (eye) ball: Study says visual system equipped with 'future seeing powers' 3Does fishing on drifting fish aggregation devices endanger the survival of tropical tuna? 2Does fishing on drifting fish aggregation devices endanger the survival of tropical tuna? 3Green tea compounds beat OSA-related brain deficits 2
Rabbit polyclonal to Peptide E ( Abpromise for all tested applications)....
Mouse monoclonal [6911] to E. coli K99 pilus ( Abpromise for all tested applications)....
...
...
Biology Products: